Lotus Pharmaceuticals

Focus: Lotus Pharmaceuticals is a Taiwan-based public generics manufacturer founded in 1966, focused on nephrology and specialized therapeutics with a portfolio anchored in kidney disease treatments.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Lotus Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Lotus Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Late-stage

6 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

CALCIUM ACETATE

Serum phosphorus control in end-stage renal disease (ESRD)

$2K Part D

Post-LOE

Core revenue driver (100% of reported revenue) but minimal Medicare Part D spend indicates severe market saturation or pricing pressure.

Help build intelligence for Lotus Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Established 58-year-old public company with stable generics revenue from FDA-approved renal disease treatments
Active pipeline spanning Phase 1-4 programs in pain, nephrology, and specialty indications with 17 active clinical trials
Geographic diversity with Taiwan headquarters providing potential exposure to Asian pharma operations

Watch Out For

Extreme revenue concentration (100% from single drug CALCIUM ACETATE) creates severe business continuity risk and limits growth opportunities
No active job openings (activeJobCount: 0) signals minimal hiring and potential organizational constraints
R&D intensity metrics unavailable and employee count unknown, making financial health and headcount trajectory impossible to assess

Generated by Claude from Lotus Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

PARICALCITOL

Secondary hyperparathyroidism in chronic kidney disease stages 3-5

Post-LOE

Multiple ANDA formulations suggest competitive generic positioning in established nephrology segment with no Part D spending data.

LEVONORGESTREL

Pregnancy prevention and heavy menstrual bleeding

Post-LOE

Contraceptive generic outside core nephrology focus; provides portfolio diversification but limited growth trajectory.

METHOTREXATE SODIUM

Refractory non-Hodgkin lymphoma

Post-LOE

Oncology generic positioned outside stated specialty but contributes to portfolio breadth in post-LOE competitive generics market.

NINTEDANIB

Pre-launch indication undisclosed

Pre-Launch

Pre-launch ANDA suggests pipeline activity in oncology or pulmonary disease; no indication data limits assessment.

MIDOSTAURIN

Pre-launch indication undisclosed

Pre-Launch

Pre-launch kinase inhibitor ANDA indicates specialty oncology expansion; regulatory timeline unknown.

Pipeline & Clinical Trials

Efficacy Evaluation of a Novel Diagnostic Assay Which is the Basis for Seaforia Diagnostic System

Male Fertility

N/A

Nutrition intervention study with a black tea extract

Healthy

N/A

Clinical Trials (1)

NCT01561300Efficacy of Brooke Bond Black Tea Extract on Flow Mediated Dilation in Indian Males

N/A

Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa

Dystrophic Epidermolysis Bullosa

N/A

Parent Child Interaction Therapy

Behavior Problem

N/A

Clinical Trials (1)

NCT04459845Early Intervention For Families Experiencing Homelessness: A Randomized Trial Comparing Two Parenting Programs

N/A

CT-044

Pain, Acute

Phase 1

Clinical Trials (1)

NCT04252833Open-label, Crossover, Food Effect Study to Evaluate CT-044 in Healthy Human Volunteers

Phase 1

FX301

Pain, Postoperative

Phase 1

Clinical Trials (1)

NCT04826328Study to Evaluate the Safety and Tolerability of FX301 in Patients Undergoing Bunionectomy

Phase 1

CT-044 HCl

Acute Pain

Phase 1

Clinical Trials (1)

NCT04175743Double-blind, Placebo-control, Study to Evaluate the Safety and Pharmacokinetics of CT-044 HCl, in Healthy Volunteers

Phase 1

Ketamine

Pain

Phase 2

Clinical Trials (1)

NCT02356965Study Testing Ketamine Sublingual Wafer After Wisdom Tooth Extraction

Phase 2

TRV130

Pain

Phase 2

Placebo

Pain

Phase 2

Clinical Trials (1)

NCT02199678A Study to Assess the Analgesic Properties of a Sublingual Wafer Formulation of Ketamine Following Third Molar Extraction

Phase 2

Intranasal Dexmedetomidine

Pain, Post-operative

Phase 2

Intranasal Dexmedetomidine

Pain, Post-operative

Phase 2

Cannabidiol

Anxiety

Phase 2

Clinical Trials (1)

NCT04267679Cannabidiol for Anxiety

Phase 2

Acarbose

The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg

Phase 3

Clinical Trials (1)

NCT01245166A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus

Phase 3

Laxymig ER

Migraine With Aura

Phase 3

Clinical Trials (1)

NCT00334178Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine

Phase 3

Ropivacaine

Bunion

Phase 3

Clinical Trials (1)

NCT05773846A Study to Evaluate Analgesic Efficacy and Safety of PRF-110 for Post-surgical Pain

Phase 3

Bupivacaine liposome

Dental Pain

Phase 3

Clinical Trials (1)

NCT02517905Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction

Phase 3

Clonidine Micropellets

Lumbosacral Radiculopathy

Phase 3

Clinical Trials (1)

NCT03727100Treatment of Pain Associated With Lumbosacral Radiculopathy in Adults

Phase 3

Norco 7.5mg/325

Post Operative Pain

Phase 3

Clinical Trials (1)

NCT02381132A Randomized, Open Label, Prospective Study to Explore the Clinical Characteristics of Oral MNK155 and Norco 7.5mg/325 When Used for the Treatment of Moderate to Severe Post Operative Pain

Phase 3

Sublingual film containing Igalmi

Bipolar Disorder

Phase 4

1% diclofenac sodium gel

Pain

Phase 4

Percocet

Post Operative Pain

Phase 4

Clinical Trials (1)

NCT02101476An Open Label, Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP( Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain.

Phase 4

Denosin® and Xyzal®

Chronic Idiopathic Urticaria

Phase 4

Clinical Trials (1)

NCT00346606The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria

Phase 4

Placebo

Dental Pain

Phase 4

Clinical Trials (1)

NCT02096926Methodological Validation of Ibuprofen Verses Placebo for Post Operative Pain After Third Molar Extraction Surgery